Sofosbuvir: a review of its use in patients with chronic hepatitis C. (Q38222679)

31 August 2017

Sofosbuvir: a review of its use in patients with chronic hepatitis C. (English)

1 reference

31 August 2017

0 references

1 reference

1

Gillian M Keating

1 reference

PubMed ID

24958336

31 August 2017

language of work or name

1 reference

1 July 2014

1 reference

31 August 2017

1 reference

31 August 2017

74

1 reference

31 August 2017

10

1 reference

31 August 2017

1127-1146

1 reference

https://scigraph.springernature.com/pub.10.1007/s40265-014-0247-z

31 August 2017

0 references

cites work

Hepatitis C virus: here comes all-oral treatment

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0247-Z

Diagnosis, management, and treatment of hepatitis C: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0247-Z

New concepts of sofosbuvir-based treatment regimens in patients with hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0247-Z

An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0247-Z

Interferon-free hepatitis C therapy: how close are we?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0247-Z

Current prospects for interferon-free treatment of hepatitis C in 2012.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0247-Z

Analysis of hepatitis C viral kinetics during administration of two nucleotide analogues: sofosbuvir (GS-7977) and GS-0938.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0247-Z

Sofosbuvir and ribavirin for hepatitis C genotype 1 in patients with unfavorable treatment characteristics: a randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0247-Z

IFNL4-ΔG genotype is associated with slower viral clearance in hepatitis C, genotype-1 patients treated with sofosbuvir and ribavirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0247-Z

Sofosbuvir for previously untreated chronic hepatitis C infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0247-Z

Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0247-Z

Sofosbuvir and ribavirin in HCV genotypes 2 and 3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0247-Z

Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0247-Z

Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0247-Z

Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0247-Z

In vivo emergence of a novel mutant L159F/L320F in the NS5B polymerase confers low-level resistance to the HCV polymerase inhibitors mericitabine and sofosbuvir

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0247-Z

Minimal impact of sofosbuvir and ribavirin on health related quality of life in chronic hepatitis C (CH-C).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0247-Z

Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0247-Z

Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0247-Z

Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0247-Z

Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0247-Z

Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0247-Z

The natural history of recurrent hepatitis C and what influences this

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0247-Z

Effects of sofosbuvir-based treatment, with and without interferon, on outcome and productivity of patients with chronic hepatitis C.

21 January 2018

1 reference

12 December 2020

EASL Clinical Practice Guidelines: management of hepatitis C virus infection

1 reference

12 December 2020

Efficacy of nucleotide polymerase inhibitor sofosbuvir plus the NS5A inhibitor ledipasvir or the NS5B non-nucleoside inhibitor GS-9669 against HCV genotype 1 infection

1 reference

12 December 2020

Chronic hepatitis C: future treatment

1 reference

12 December 2020

A SPECIAL MEETING REVIEW EDITION: Advances in the Treatment of Hepatitis C Virus Infection From EASL 2014: The 49th Annual Meeting of the European Association for the Study of the Liver • April 9-13, 2014 • London, United KingdomSpecial Reporting on

1 reference

12 December 2020

10.1007/S40265-014-0247-Z

Identifiers

DOI

1 reference

PubMed ID

24958336

Dimensions Publication ID

31 August 2017

0 references

1 reference

PubMed ID

24958336